



Wes Moore, Governor · Aruna Miller, Lt. Governor · Meena Seshamani, M.D., Ph.D., Secretary

Maryland Board of Pharmacy
Akash Patel, PharmD, Board President
Deena Speights-Napata, M.A., Executive Director
4201 Patterson Avenue
Baltimore, MD 21215-2299

September 4, 2026

VIA REGULAR & CERTIFIED MAIL
RETURN RECEIPT REQUESTED
ARTICLE #: 7019 2280 0000 6567 0860

Vici Health Services, LLC
6679 Santa Barbara Road, Suite J
Elkridge, Maryland 21075
Attn: Francesca Minale, President

RE: Findings of Deficiencies and Imposition of Civil Monetary Penalty
By Consent
Permit No. P09006
Case No. 26-169

Dear Ms. Minale:

The Maryland Board of Pharmacy (the “Board”) conducted an annual inspection of Vici Health Services, LLC (the “Pharmacy”) on October 24, 2025, for compliance with statutes and regulations governing the operation of a pharmacy. The Board’s inspection report indicated that the Pharmacy was not compliant with laws relating to pharmacy operations, security/access, and required Board notifications. Specifically, the inspector noted that the Pharmacy premises had been significantly altered from the premises approved at the Pharmacy’s opening inspection. The Pharmacy failed to provide notification of changes to its establishment as required by COMAR 10.34.30.05. The inspector identified several issues with the unapproved premises that indicate noncompliance with pharmacy security and access laws to include: (1) the prescription compounding area was located outside the unapproved Pharmacy premises and shared with non-pharmacy personnel; (2) the unapproved Pharmacy did not have a dedicated medication refrigerator; (3) the unapproved Pharmacy did not have an alarm system - only badge access; (4) the Pharmacy’s CDS cage was located outside the unapproved Pharmacy premises; (5) non-pharmacy personnel had access to the unapproved Pharmacy premises, the CDS cage, and the prescription compounding area; and (6) security access to the unapproved Pharmacy, CDS cage, and prescription areas was not limited to licensed pharmacists.

Furthermore, the Board’s inspector requested certain documentation relating to the compounding processes in furtherance of the inspection which was not timely provided.

The Board and the Pharmacy participated in a case resolution conference resulting in an agreement to resolve the findings of deficiencies as set forth herein.

I. FINDINGS AND CONCLUSION

The Board finds that the Pharmacy failed to notify the Board of significant structural changes to its facility as required. The Pharmacy's unauthorized changes to its facility failed to comply with security and restricted access requirements of the Board by: (1) allowing non-pharmacists to have security access to the Pharmacy, CDS cage and compounding area; (2) allowing non-pharmacy personnel to have access to the Pharmacy premises; (3) failing to have an active security alarm system for the Pharmacy premises; and (4) failing to have a dedicated medication refrigerator for the Pharmacy.

Based upon the findings above, the Board concludes that the Pharmacy is in violation of the Maryland Pharmacy Act and the regulations adopted thereunder. Specifically, the Board finds the Pharmacy in violation of Health Occ. Art., §§ 12-403(c)(1), (3), (4), (12), 12-413(c), and COMAR 10.34.05 and 10.34.30.05.

II. CIVIL MONETARY PENALTY

Under Maryland Health Occupations Article § 12-410 and COMAR 10.34.11, the Board of Pharmacy has the authority to impose a civil monetary penalty based upon violations of the Maryland Pharmacy Act.

Based upon the deficiencies reported at the Pharmacy, the Board hereby imposes, by agreement, a **civil monetary penalty of \$2,500.00**. The deficiencies upon which the civil monetary penalty are based are set forth in this Finding and the inspection report dated October 24, 2025.

In determining the recommended civil monetary penalty, the Board took into consideration the aggregating and mitigating factors outlined in COMAR 10.34.11.08.

III. FOLLOW-UP ACTIONS AND INSPECTION

The Pharmacy shall submit to the Board a copy of the Pharmacy's updated blueprint of its current floorplan and undergo and pass an inspection of the new premises. Until that time, the Pharmacy's premises and operations shall be based on the original blueprint that was approved by the Board. The Pharmacy shall also submit a copy of the IRB that supports its research compounding practices. (The Board notes that the Pharmacy has submitted an IRB.)

Please be advised that the Board of Pharmacy may perform a follow-up inspection of the Pharmacy to ensure that the deficiencies noted herein have been addressed and corrected. Should the follow-up inspection indicate that the Pharmacy has further deficiencies, the Board may pursue further disciplinary action against the Pharmacy that may result in the imposition of sanctions such as suspension, revocation or additional monetary penalties.

IV. PAYMENT OF MONETARY PENALTY

The Pharmacy has agreed to pay the above civil monetary penalty within thirty (30) days of the date of this Finding, in the form of a check or money order made payable to the Maryland Board of Pharmacy.

Please mail the check or money order to:

Santander Bank
Attn: State of Maryland - Board of Pharmacy
Lockbox Operations – Box #2051
101 Woodcrest Road, Suite 201
Cherry Hill, New Jersey 08003

NOTE: Please include the case number 26-169 on your check or money order to ensure proper assignment to your case.

Upon the Pharmacy's payment of the civil monetary penalty, this Finding will constitute the Board's final action with respect to the October 24, 2025, inspection report and shall be a final order and public document under the Maryland Public Information Act, Md. Code Ann., General Provisions Art. § 4-101 *et seq.*, and posted and reported in accordance with State and federal laws.

If you have any questions concerning the instructions contained in this letter, please contact Trina Leak, Pharm.D., Compliance Director, at trina.leak1@maryland.gov or 443-635-8318.

Sincerely,



Deena Speights-Napata, M.A.
Executive Director